[Report] Drug Endocrine Treatments & Metabolic Diseases Market Research, Trends, Analysis TOC

INTRODUCTION
- OBJECTIVES AND GOALS OF THE STUDY
- CONTRIBUTION OF THE STUDY AND FOR WHOM
- SCOPE AND CONTENT
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC PUBLICATIONS
- DISCLAIMER
EXECUTIVE SUMMARY
- Summary Table:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Summary Figure:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
OVERVIEW
- THE ENDOCRINE SYSTEM
  - ROLE OF THE HYPOTHALAMUS IN ENDOCRINE FUNCTION
- Table 1 HYPOTHALAMIC NEUROHORMONES
  - TYPES AND ACTIVITIES OF NEUROHORMONES PRODUCED BY THE HYPOTHALAMUS
- ENDOCRINE DISEASES
  - HYPERTENSION
    - Hypertension (Continued)
    - The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
- Table 2 EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS
  - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
- Table 3 CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER
  - INFERTILITY
    - Prevalence of Infertility
    - Causes of Infertility
      - Infertility Factors
      - Female Factors
        
        Tubal Factors
        Ovulation Factors
        Amenorrhea
        Amenorrhea (Continued)
        Amenorrhea (Continued)
        Anovulation
- Table 4 CLASSIFICATION OF CHRONIC ANOVULATION
  - Luteal Phase Dysfunction
    - Endometriosis
      - Endometriosis (Continued)
    - Fibroids
    - Other and Unknown Factors
      - Cervical Factors
      - The Role of Relaxin
      - Male Factors
        
        Varicocele
        Genetic Factors
        Microdeletions of the Y-Chromosome
        Congenital Bilateral Absence of the Vas Deferens
        A-MYB Gene and its Relation to Male Infertility
        Reduced Spermatogenesis
        Hypogonadism
        Environmental Factors
        Treatment Protocols
- THYROID DISORDERS
  - Functions of the Thyroid Hormones
  - Clinical Evaluation of Thyroid Disorders
- Table 5 LABORATORY EVALUATION OF THYROID DISORDERS
  - Hyperthyroidism
- Table 6 CLASSIFICATION OF HYPERTHYROIDISM
  - Graves' Disease
  - Hypothyroidism
  - Thyroiditis
- METABOLIC DISEASES
  - HYPERCHOLESTEROLEMIA
    - Hypercholesterolemia (Continued)
    - Hypercholesterolemia (Continued)
    - Relationship of Cholesterol to Cardiovascular Disease
  - OBESITY
    - Drug Treatment for Obesity
    - Alternative Treatments for Obesity
  - METABOLIC SYNDROME
- Table 7 BODY MASS INDEX RATIOS AND CLASSIFICATION OF OBESITY
  - METABOLIC SYNDROME (CONTINUED)
ENDOCRINE DISEASES - APPLICATIONS AND PRODUCTS
- HYPERTENSION
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERTENSION
    - Adrenergic Inhibitors
- Table 8 SELECTED ADRENERGIC INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
  - The Market for Adrenergic Inhibitors
- Table 9 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, 2004-2011 ($ MILLIONS)
  - Angiotensin-Converting Enzyme Inhibitors
    - Angiotensin-Converting Enzyme Inhibitors (Continued)
- Table 10 SELECTED ACE INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
  - The Market for ACE Inhibitors
- Table 11 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FOR ACE INHIBITORS, 2004-2011 ($ MILLIONS)
  - Angiotensin II Receptor Antagonists
    - The Difference Between ACE Inhibitors and Angiotensin II Inhibitors
    - The Market for Angiotensin II Inhibitors
- Table 12 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, 2004-2011 ($ MILLIONS)
  - Beta Blockers
- Table 13 SELECTED BETA BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
  - Usage Trends of Beta Blockers
  - The Market for Beta Blockers
- Table 14 GLOBAL MARKET FOR BETA BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FOR BETA BLOCKERS, 2004-2011 ($ MILLIONS)
  - Calcium Channel Blockers
- Table 15 SELECTED CALCIUM CHANNEL BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 15 (CONTINUED)
  - Calcium Channel Blocker Usage
  - The Market for Calcium Channel Blockers
- Table 16 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Figure 5 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, 2004-2011 ($ MILLIONS)
  - Combination Products
    - The Market for Combination Antihypertensive Products
- Table 17 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, THROUGH 2011 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, 2004-2011 ($ MILLIONS)
  - Treatment Regimens
  - The Market for Selected Drugs to Treat Hypertension
- Table 18 GLOBAL MARKET FOR SELECTED PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 19 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, 2004-2011 ($ MILLIONS)
  - Products in Development for the Treatment of Hypertension
- Table 20 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
  - Aliskiren
  - Clevelox
  - Darusentan
  - Imidapril
  - Nebivolol
  - PW2101
  - Tadalafil
- INFERTILITY
  - ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 21 CURRENTLY AVAILABLE ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 21 (CONTINUED)
- Table 22 U.S. ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURE VOLUMES, THROUGH 2011
- Table 22 (CONTINUED)
  - Success Rates for ART
- Table 23 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, 1998
- Table 24 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, NONDONER EGGS, 2003
- Table 25 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, DONOR EGGS, 2003
  - Success Rates for ART (Continued)
  - Success Rates for ART (Continued)
    - Semen Processing
    - Intrauterine Insemination
    - In Vitro Fertilization
      - In Vitro Fertilization (Continued)
- Table 26 EFFECT OF PREVIOUS UNSUCCESSFUL IVF ATTEMPTS ON LIVE BIRTH RATE PER CYCLE
- Table 27 EFFECT OF AGE OF WOMAN ON IVF LIVE BIRTH RATE PER CYCLE
- Table 28 EFFECT OF CAUSE OF IVF INFERTILITY ON LIVE BIRTH RATE PER CYCLE
- Table 29 U.S. IN VITRO FERTILIZATION PROCEDURE VOLUMES, THROUGH 2006
  - Ooplasmic Transfer
  - Gamete Intrafallopian Tube Transfer
  - Zygote Intrafallopian Transfer
- Table 30 U.S. GAMETE INTRAFALLOPIAN TRANSFER AND ZYGOTE INTRAFALLOPIAN TRANSFER PROCEDURE VOLUMES, THROUGH 2006
  - Tubal Embryo Transfer
  - Intracytoplasmic Sperm Injection
- U.S. FERTILITY CLINICS SERVE THE WORLD MARKET
- THE FUTURE OF BIOTECH IN REPRODUCTIVE TECHNOLOGY
- LEGAL ENVIRONMENT
- THE INFERTILITY TREATMENT MARKET
  - Current Status of the Infertility Market
  - Fertility Treatment Market Projections
- Table 31 U.S. MARKET FOR INFERTILITY TREATMENT, THROUGH 2011 ($ MILLIONS)
- Table 32 U.S. COSTS OF INFERTILITY DIAGNOSTICS AND TREATMENTS, 2005 ($)
  - FERTILITY DRUGS
- Table 33 SELECTED PHARMACEUTICAL AGENTS FOR THE TREATMENT OF FEMALE INFERTILITY
- Table 33 (CONTINUED)
  - Major Participants in the Fertility Drug Market
- Table 34 MANUFACTURERS OF FERTILITY DRUGS AND THEIR PRODUCTS
- Table 34 (CONTINUED)
  - Genetically Engineered Products Take Over the Market
  - Increasing Focus on the Treatment of Male Infertility
    - Leading Fertility Drugs
- Table 35 LEADING FERTILITY DRUGS BY INDICATION
  - Bromocryptine Mesylate
  - Cetrotide
  - Chlorotriansene
  - Clomiphene Citrate
  - Danazol
  - Estrogens
    - Estradiol Valerate
    - Esterified Estrogens
    - Estrone
    - Estropipate
    - Ethinyl Estradiol
    - Gonadorelin Acetate
  - Gonadotropins
- Table 36 GONADOTROPIN USAGE IN SELECTED COUNTRIES (ESTIMATED NUMBER OF AMPOULES PER 1,000 INHABITANTS)
  - Recombinant Follicle-Stimulating Hormones
    - Recombinant Follicle-...(Continued)
  - Gonadotropin, Chorionic
  - Gonadotropin-Releasing Hormone Antagonist
  - Luteinizing Hormone-Releasing Hormone Antagonist
    - Goserelin Acetate
    - Leuprolide Acetate
  - Menotropins
  - Nafarelin Acetate
  - Ovidrel/Ovitrelle
  - Progesterone
    - Progesterone (Continued)
  - Quinestrol
  - Urofollitropin
    - The Global Market for Fertility Drugs
- Table 37 GLOBAL SALES OF SELECTED FERTILITY DRUGS, THROUGH 2011
- Table 38 GEOGRAPHIC SHARES OF INFERTILITY PHARMACEUTICALS, THROUGH 2011 ($ MILLIONS)
  - Leading Global Marketers of Fertility Drugs
- Figure 8 INFERTILITY DRUGS: GLOBAL SUPPLIER MARKET SHARES, 2005 (PERCENT)
  - Fertility Drugs in Development
- Table 39 FERTILITY DRUGS IN PHASE II OR LATER DEVELOPMENT
  - FSH-CTP
  - Visanne
  - Vitropin
    - Ovarian Implants as a Treatment for Infertility
- THYROID DISEASE
  - HYPERTHYROIDISM
    - Drugs Used to Treat Hyperthyroidism
    - The Market for Drugs to Treat Hyperthyroidism
- Table 40 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERTHYRODISM, THROUGH 2011 ($ MILLIONS)
  - Products in Development for the Treatment of Hyperthyroidism
- HYPOTHYROIDISM
  - Drugs Used to Treat Hypothyroidism
- Table 41 DRUGS USED TO TREAT HYPOTHYROIDISM
  - Levothyroxine
  - Liothyronine
  - Liotrix
  - Natural Thyroid
    - Synthroid Gains FDA Approval Decades After its Market Introduction
  - The Market for Prescription Drugs to Treat Hypothyroidism
- Table 42 GLOBAL SALES OF SELECTED DRUGS TO TREAT HYPOTHYROIDISM, THROUGH 2011
  - Prescription Products in Development for the Treatment of Hypothyroidism
METABOLIC DISEASES - APPLICATIONS AND PRODUCTS
- HYPERCHOLESTEROLEMIA
  - PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 43 CLASSES OF LIPID-LOWERING DRUGS
- Table 43 (CONTINUED)
  - Bile Acid-Binding Resins
  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
    - U.S. Marketed Statin Drugs
- Table 44 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
  - Fibric Acids
  - Nicotinic Acid and Derivatives
  - Probucol
  - Currently Marketed Antihyperlipidemic Drugs
- Table 45 ANTIHYPERLIPIDEMIC DRUGS ON THE MARKET
- Table 45 (CONTINUED)
  - Leading Products
  - Combination Products
  - Research and Development
    - Statin Drugs Show Promise in Treating Prostate Cancer
    - The Entry of Generic Versions of Blockbuster Cholesterol Drugs
    - Blockbuster Cholesterol Drugs (Continued)
      - The Medicare (Part D) Drug Benefit and Statin Drugs
  - THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERCHOLESTEROLEMIA
- Table 46 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 47 U.S. MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
  - PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
- Table 48 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
  - AGI-1067
  - Avasimibe
  - CETi-1
  - ETC-216
  - ETC-588
  - ETC-642
  - FM-VP4
  - KS 01-019
  - Lipitor/Torcetrapib
  - MK-524B
- OBESITY
  - MARKETED DRUGS FOR THE TREATMENT OF OBESITY
    - Meridia
    - Xenical
    - Other Products
  - THE MARKET FOR DRUGS TO TREAT OBESITY
- Table 49 GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY, THROUGH 2011 ($ MILLIONS)
  - DRUGS IN DEVELOPMENT FOR THE TREATMENT OF OBESITY
    - Cannabinoid (CB1) Antagonists
- Table 51 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF OBESITY
  - Acomplia
  - ADP356
  - AOD9604
  - ATL-962
  - Cetilistat
  - CP 945598
  - GI 181771
  - HMR 1426
  - P 57
  - Peptide YY3-36
  - S-2367
  - Symlin
  - Tesofensine
  - TM30338
  - Drugs for Other Indications Prescribed Off-Label for the Treatment of Obesity
  - Discontinued Products in Development
    - GlaxoSmithKline Submits Application for an Over-the-Counter Version of Xenical
COMPANY PROFILES
- ABBOTT LABORATORIES
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- AMYLIN PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- ARENA PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 52 ARENA PHARMACEUTICALS DRUG-DEVELOPMENT PIPELINE
  - CORPORATE STRATEGY
- ATHEROGENICS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- BRISTOL-MYERS SQUIBB
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- FERRING PHARMACEUTICALS AS
  - BUSINESS OVERVIEW
  - CORPORATE STRATEGY
- GLAXOSMITHKLINE, PLC
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- KING PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- KOS PHARMACEUTICALS, INC.
  - BUSINESS OVERVIEW
  - PRODUCTS
  - CORPORATE STRATEGY
- MERCK & COMPANY, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 53 MERCK' S DRUGS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
- MYOGEN, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- NOVARTIS AG
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- ORGANON INTERNATIONAL
  - BUSINESS OVERVIEW
  - PRODUCTS
  - CORPORATE STRATEGY
- PFIZER CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- SCHERING-PLOUGH CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
  - CORPORATE STRATEGY
- SERONO S.A.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - PRODUCTS
- Table 54 SERONO PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  - CORPORATE STRATEGY
LIST OF TABLES
- Summary Table:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Table 1 HYPOTHALAMIC NEUROHORMONES
- Table 2 EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS
- Table 3 CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER
- Table 4 CLASSIFICATION OF CHRONIC ANOVULATION
- Table 5 LABORATORY EVALUATION OF THYROID DISORDERS
- Table 6 CLASSIFICATION OF HYPERTHYROIDISM
- Table 7 BODY MASS INDEX RATIOS AND CLASSIFICATION OF OBESITY
- Table 8 SELECTED ADRENERGIC INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
- Table 9 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 10 SELECTED ACE INHIBITORS: PRECAUTIONS AND SIDE EFFECTS
- Table 11 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 12 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, THROUGH 2011 ($ MILLIONS)
- Table 13 SELECTED BETA BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 14 GLOBAL MARKET FOR BETA BLOCKERS, THROUGH 2011 ($ MILLIONS)
- Table 15 SELECTED CALCIUM CHANNEL BLOCKERS: PRECAUTIONS AND SIDE EFFECTS
- Table 16 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, THROUGH 2011 (MILLIONS)
- Table 17 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, THROUGH 2011 ($ MILLIONS)
- Table 18 GLOBAL MARKET FOR SELECTED PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 19 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
- Table 20 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
- Table 21 CURRENTLY AVAILABLE ASSISTED REPRODUCTIVE TECHNOLOGIES
- Table 22 U.S. ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURE VOLUMES, THROUGH 2011
- Table 23 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, 1998
- Table 24 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, NONDONER EGGS, 2003
- Table 25 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, DONOR EGGS, 2003
- Table 26 EFFECT OF PREVIOUS UNSUCCESSFUL IVF ATTEMPTS ON LIVE BIRTH RATE PER CYCLE
- Table 27 EFFECT OF AGE OF WOMAN ON IVF LIVE BIRTH RATE PER CYCLE
- Table 28 EFFECT OF CAUSE OF IVF INFERTILITY ON LIVE BIRTH RATE PER CYCLE
- Table 29 U.S. IN VITRO FERTILIZATION PROCEDURE VOLUMES, THROUGH 2006
- Table 30 U.S. GAMETE INTRAFALLOPIAN TRANSFER AND ZYGOTE INTRAFALLOPIAN TRANSFER PROCEDURE VOLUMES, THROUGH 2006
- Table 31 U.S. MARKET FOR INFERTILITY TREATMENT, THROUGH 2011 ($ MILLIONS)
- Table 32 U.S. COSTS OF INFERTILITY DIAGNOSTICS AND TREATMENTS, 2005 ($)
- Table 33 SELECTED PHARMACEUTICAL AGENTS FOR THE TREATMENT OF FEMALE INFERTILITY
- Table 34 MANUFACTURERS OF FERTILITY DRUGS AND THEIR PRODUCTS
- Table 35 LEADING FERTILITY DRUGS BY INDICATION
- Table 36 GONADOTROPIN USAGE IN SELECTED COUNTRIES (ESTIMATED NUMBER OF AMPOULES PER 1,000 INHABITANTS)
- Table 37 GLOBAL SALES OF SELECTED FERTILITY DRUGS, THROUGH 2011
- Table 38 GEOGRAPHIC SHARES OF INFERTILITY PHARMACEUTICALS, THROUGH 2011 ($ MILLIONS)
- Table 39 FERTILITY DRUGS IN PHASE II OR LATER DEVELOPMENT
- Table 40 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERTHYRODISM, THROUGH 2011 ($ MILLIONS)
- Table 41 DRUGS USED TO TREAT HYPOTHYROIDISM
- Table 42 GLOBAL SALES OF SELECTED DRUGS TO TREAT HYPOTHYROIDISM, THROUGH 2011
- Table 43 CLASSES OF LIPID-LOWERING DRUGS
- Table 44 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
- Table 45 ANTIHYPERLIPIDEMIC DRUGS ON THE MARKET
- Table 46 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 47 U.S. MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
- Table 48 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
- Table 49 GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY, THROUGH 2011 ($ MILLIONS)
- Table 51 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF OBESITY
- Table 52 ARENA PHARMACEUTICALS DRUG-DEVELOPMENT PIPELINE
- Table 53 MERCK' S DRUGS IN PHASE II OR LATER DEVELOPMENT
- Table 54 SERONO PRODUCTS IN PHASE II OR LATER DEVELOPMENT
LIST OF FIGURES
- Summary Figure:
- GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
- Figure 1 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 2 GLOBAL MARKET FOR ACE INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 3 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, 2004-2011 ($ MILLIONS)
- Figure 4 GLOBAL MARKET FOR BETA BLOCKERS, 2004-2011 ($ MILLIONS)
- Figure 5 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, 2004-2011 ($ MILLLIONS)
- Figure 6 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, 2004-2011 ($ MILLIONS)
- Figure 7 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, 2004-2011 ($ MILLIONS)
- Figure 8 INFERTILITY DRUGS: GLOBAL SUPPLIER MARKET SHARES, 2005 (PERCENT)

Drug Treatments for Leading Endocrine and Metabolic Diseases

Table of Contents